CITATION REPORT
List of articles citing

Longitudinal proteomic analysis of severe COVID-19 reveals survival-associated signatures, tissue-specific cell death, and cell-cell interactions

#	Paper	IF	Citations
119	Plasma Proteomics of COVID-19 Associated Cardiovascular Complications: Implications for Pathophysiology and Therapeutics. **2021**,		1
118	Next generation plasma proteome profiling of COVID-19 patients with mild to moderate symptoms.		1
117	Using ʧig dataʨto disentangle aging and COVID-19. **2021**, 1, 496-497		2
116	SARS-CoV-2 RNAemia and proteomic trajectories inform prognostication in COVID-19 patients admitted to intensive care. **2021**, 12, 3406		41
115	Plasma P-selectin is an early marker of thromboembolism in COVID-19. **2021**,		1
114	SARS-CoV-2 viremia is associated with distinct proteomic pathways and predicts COVID-19 outcomes. **2021**, 131,		27
113	High-dose intravenous immunoglobulins might modulate inflammation in COVID-19 patients. **2021**, 4,		4
112	Vaccine serologic responses among transplant patients associate with COVID-19 infection and T peripheral helper cells. **2021**,		6
111	Immuno-proteomic profiling reveals abundant airway CD8 T cells and ongoing epithelial injury in prolonged post-COVID19 respiratory disease.		0
110	Harnessing the Potential of Multiomics Studies for Precision Medicine in Infectious Disease. **2021**, 8, ofab483		0
109	A Potential Role of the CD47/SIRPalpha Axis in COVID-19 Pathogenesis. **2021**, 43, 1212-1225		3
108	Deep immune profiling reveals early-stage and highly coordinated immune responses in mild COVID-19 patients.		
107	Early cross-coronavirus reactive signatures of humoral immunity against COVID-19. **2021**, 6, eabj2901		22
106	Systems and Longitudinal Analysis Reveals Early-Stage and Highly Coordinated Immune Responses in Mild COVID-19 Patients.		
105	Longitudinal characterization of circulating neutrophils uncovers distinct phenotypes associated with disease severity in hospitalized COVID-19 patients. **2021**,		5
104	Plasma P-selectin is an early marker of thromboembolism in COVID-19. **2021**, 96, E468-E471		4
103	Advances and Utility of the Human Plasma Proteome. **2021**, 20, 5241-5263		16

102   The Role of Epithelial Damage in the Pulmonary Immune Response. **2021**, 10,   4

101   Circulating proteins to predict adverse COVID-19 outcomes.   0

100   Proximity Extension Assay in Combination with Next-Generation Sequencing for High-throughput Proteome-wide Analysis. **2021**, 20, 100168   4

99   Association of cardiometabolic microRNAs with COVID-19 severity and mortality. **2021**,   6

98   Precise blood proteome profiling in an undiagnosed population with COVID-19.   1

97   Next generation plasma proteome profiling of COVID-19 patients with mild to moderate symptoms. **2021**, 74, 103723   3

96   Identification of Robust Protein Associations With COVID-19 Disease Based on Five Clinical Studies.. **2021**, 12, 781100   2

95   Immuno-proteomic profiling reveals aberrant immune cell regulation in the airways of individuals with ongoing post-COVID-19 respiratory disease.. **2022**,   9

94   Modeling SARS-CoV-2 spike/ACE2 protein-protein interactions for predicting the binding affinity of new spike variants for ACE2, and novel ACE2 structurally related human protein targets, for COVID-19 handling in the 3PM context.. **2022**, 13, 1-27   2

93   ELF5 is a respiratory epithelial cell-specific risk gene for severe COVID-19.   0

92   Quantitative plasma proteome profiling of COVID-19 patients with mild and moderate symptoms.. **2021**, 75, 103773

91   A knowledge graph to interpret clinical proteomics data.. **2022**,   7

90   A blood atlas of COVID-19 defines hallmarks of disease severity and specificity.. **2022**, 185, 916-938.e58   17

89   Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus.. **2022**,   22

88   Single-Cell Differential Network Analysis with Sparse Bayesian Factor Models.. **2021**, 12, 810816

87   Alveolar, Endothelial, and Organ Injury Marker Dynamics in Severe COVID-19. **2021**,   5

86   Th1, Th2 and Th17 inflammatory pathways synergistically predict cardiometabolic protein expression in serum of COVID-19 patients.. **2022**,   0

85   OUP accepted manuscript.   2

84	Prognostic tools and candidate drugs based on plasma proteomics of patients with severe COVID-19 complications.. **2022**, 13, 946	2
83	Cell specific peripheral immune responses predict survival in critical COVID-19 patients.. **2022**, 13, 882	2
82	Host and microbiome features of secondary infections in lethal covid-19.	0
81	Specialized interferon action in COVID-19.. **2022**, 119,	7
80	COVIDomics: The Proteomic and Metabolomic Signatures of COVID-19.. **2022**, 23,	5
79	How Is Mass Spectrometry Tackling the COVID-19 Pandemic?. **2022**, 2,	0
78	Endothelial Damage in Sepsis: The Importance of Systems Biology.. **2022**, 10, 828968	1
77	Proteome reveals antiviral host response and NETosis during acute COVID-19 in high-risk patients.	
76	An engineered ACE2 decoy receptor can be administered by inhalation and potently targets the BA.1 and BA.2 omicron variants of SARS-CoV-2.. **2022**,	2
75	Combinatorial analysis reveals highly coordinated early-stage immune reactions that predict later antiviral immunity in mild COVID-19 patients.. *Cell Reports Medicine*, **2022**, 3, 100600	18	0
74	FcR-mediated SARS-CoV-2 infection of monocytes activates inflammation.. **2022**,	20
73	Clinical characteristics with inflammation profiling of Long-COVID and association with one-year recovery following hospitalisation in the UK: a prospective observational study.	2
72	SOMAmer reagents and the SomaScan platform: Chemically modified aptamers and their applications in therapeutics, diagnostics, and proteomics. **2022**, 171-260	0
71	Asymptomatic SARS-CoV-2 Infection Is Associated With Higher Levels of Serum IL-17C, Matrix Metalloproteinase 10 and Fibroblast Growth Factors Than Mild Symptomatic COVID-19.. **2022**, 13, 821730	1
70	Cytokine Elevation in Severe COVID-19 From Longitudinal Proteomics Analysis: Comparison With Sepsis.. **2021**, 12, 798338	0
69	Liver damage in patients with COVID-19. **2022**,	
68	Pre-analytical processing of plasma and serum samples for combined proteome and metabolome analysis.	
67	Mapping the epithelial-immune cell interactome upon infection in the gut and the upper airways.. **2022**, 8, 15	0

66	Multi-omics identify LRRC15 as a COVID-19 severity predictor and persistent pro-thrombotic signals in convalescence.	0
65	Classification and severity progression measure of COVID-19 patients using pairs of multi-omic factors. 1-31	
64	Plasma Proteomics of COVID-19-Associated Cardiovascular Complications: Implications for Pathophysiology and Therapeutics.. **2022**,	2
63	Proteomic profiling of lung diffusion impairment in the recovery stage of SARS-CoV-2-induced ARDS.. **2022**, 12, e838	1
62	Chemokines, Soluble PD-L1, and Immune Cell Hyporesponsiveness are Distinct Features of SARS-CoV-2 Critical Illness.	2
61	Rise of the SARS-CoV-2 Variants: Can proteomics be the silver bullet?.	0
60	Phenotypic and Immunometabolic Aspects on Stem Cell Memory and Resident Memory CD8+ T Cells. 13,	
59	Unraveling protein dynamics to understand the brain the next molecular frontier. **2022**, 17,	0
58	Resistin Associated With Cytokines and Endothelial Cell Adhesion Molecules Is Related to Worse Outcome in COVID-19. 13,	1
57	Proteome-wide Mendelian randomization implicates nephronectin as an actionable mediator of the effect of obesity on COVID-19 severity.	0
56	Microvascular and proteomic signatures overlap in COVID-19 and bacterial sepsis: the MICROCODE study.	1
55	The Kinetics of SARS-CoV-2 Antibody Development Is Associated with Clearance of RNAemia.	0
54	Insights into Endotheliopathy in COVID-19.	0
53	Proteomic analysis of cardiometabolic biomarkers and predictive modeling of severe outcomes in patients hospitalized with COVID-19. **2022**, 21,	
52	Combining Deep Phenotyping of Serum Proteomics and Clinical Data via Machine Learning for COVID-19 Biomarker Discovery. **2022**, 23, 9161	1
51	ELF5 is a potential respiratory epithelial cell-specific risk gene for severe COVID-19. **2022**, 13,	0
50	Long-term changes in plasma proteomic profiles in premenopausal and postmenopausal Black and White women: the Atherosclerosis Risk in Communities study. Publish Ahead of Print,	
49	Host and microbiome features of secondary infections in lethal covid-19. **2022**, 25, 104926	0

48	Targeted plasma proteomics reveals upregulation of distinct inflammatory pathways in people living with HIV. **2022**, 25, 105089	1
47	Serum ACE2 Level is Associated With Severe SARS-CoV-2 Infection: A Cross-Sectional Observational Study. **2022**, 17, 117727192211251	0
46	COVIDpro: Database for mining protein dysregulation in patients with COVID-19.	0
45	An ACE2 decoy can be administered by inhalation and potently targets omicron variants of SARS-CoV -2.	1
44	Plasma proteomic signature predicts who will get persistent symptoms following SARS-CoV-2 infection. **2022**, 104293	3
43	The dynamic changes and sex differences of 147 immune-related proteins during acute COVID-19 in 580 individuals. **2022**, 19,	0
42	In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer.	0
41	A tissue injury repair pathway distinct but parallel to host pathogen defense.	0
40	Levels of soluble complement regulators predict severity of COVID-19 symptoms. 13,	0
39	Tocilizumab treatment leads to early resolution of myeloid dysfunction and lymphopenia in patients hospitalized with COVID-19.	0
38	Targeted proteomics identifies circulating biomarkers associated with active COVID-19 and post-COVID-19. 13,	0
37	Proteomic Analysis of Pleural Effusions from COVID-19 Deceased Patients: Enhanced Inflammatory Markers. **2022**, 12, 2789	0
36	Combination of WFDC2, CHI3L1, and KRT19 in Plasma Defines a Clinically Useful Molecular Phenotype Associated with Prognosis in Critically Ill COVID-19 Patients.	0
35	Proteomic analysis identifies a signature of disease severity in the plasma of COVID-19 pneumonia patients associated to neutrophil, platelet and complement activation. **2022**, 19,	1
34	The role of machine learning in advancing precision medicine with feedback control. **2022**, 3, 101149	0
33	Association of miR-144 levels in the peripheral blood with COVID-19 severity and mortality. **2022**, 12,	0
32	Temporal Associations of Plasma Levels of the Secreted Phospholipase A2Family and Mortality in Severe COVID-19.	0
31	Application of Aligned-UMAP to longitudinal biomedical studies.	0

30	Multi-omics identify falling LRRC15 as a COVID-19 severity marker and persistent pro-thrombotic signals in convalescence. **2022**, 13,	1
29	Pre-analytical processing of plasma and serum samples for combined proteome and metabolome analysis. 9,	0
28	Crowdsourcing Temporal Transcriptomic Coronavirus Host Infection Data: resources, guide, and novel insights.	0
27	COVID-19 plasma proteome reveals novel temporal and cell-specific signatures for disease severity and high-precision disease management.	0
26	COVID-19 Associated Myocarditis Clinical Outcomes among Hospitalized Patients in the United States: A Propensity Matched Analysis of National Inpatient Sample. **2022**, 14, 2791	0
25	Targeting TBK1 to overcome resistance to cancer immunotherapy.	1
24	Benchmarking of Machine Learning classifiers on plasma proteomic for COVID-19 severity prediction through interpretable artificial intelligence. **2023**, 102490	0
23	Plasma Proteome of Long-covid Patients Indicates Hypoxia-mediated Vasculo-proliferative Disease With Impact on Brain and Heart Function.	0
22	Optimization of Machine Learning Algorithms for Proteomic Analysis Using TOPSIS. **2022**, 9, E7-E11	0
21	Use of Monoclonal Antibodies in Immunocompromised Patients Hospitalized with Severe COVID-19: A Retrospective Multicenter Cohort. **2023**, 12, 864	0
20	Proteomic understanding of SARS-CoV-2 infection and COVID-19: Biological, diagnostic, and therapeutic perspectives. **2023**, 61-85	0
19	Analysis of inflammatory protein profiles in the circulation of COVID-19 patients identifies patients with severe disease phenotypes.	0
18	Elevated IFNA1 and suppressed IL12p40 associated with persistent hyperinflammation in COVID-19 pneumonia. 14,	0
17	Microscale combinatorial stimulation of human myeloid cells reveals inflammatory priming by viral ligands. **2023**, 9,	0
16	Identifying Early Infections in the Setting of CRS With Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL. **2023**, 7, e858	0
15	NULISA: a novel proteomic liquid biopsy platform with attomolar sensitivity and high multiplexing.	0
14	Understanding the mechanisms for COVID-19 vaccine's protection against infection and severe disease. **2023**, 22, 186-192	0
13	Proteome-wide Mendelian randomization implicates nephronectin as an actionable mediator of the effect of obesity on COVID-19 severity. **2023**, 5, 248-264	0

| 12 | Targeted plasma proteomics reveals signatures discriminating COVID-19 from sepsis with pneumonia. **2023**, 24, | 0 |

| 11 | The role of immune activation and antigen persistence in acute and long COVID. 108155892311580 | 0 |

| 10 | Humans with inherited MyD88 and IRAK-4 deficiencies are predisposed to hypoxemic COVID-19 pneumonia. **2023**, 220, | 0 |

| 9 | Plasma proteomics of SARS-CoV-2 infection and severity reveals impact on Alzheimer's and coronary disease pathways. **2023**, 26, 106408 | 0 |

| 8 | Regulatory T Cells (Tregs) and COVID-19: Unveiling the Mechanisms, and Therapeutic Potentialities with a Special Focus on Long COVID. **2023**, 11, 699 | 0 |

| 7 | A Complement Atlas identifies interleukin 6 dependent alternative pathway dysregulation as a key druggable feature of COVID-19. | 0 |

| 6 | Development of a biomarker signature using grating-coupled fluorescence plasmonic microarray for diagnosis of MIS-C. 11, | 0 |

| 5 | Targeted Blood Plasma Proteomics and Hemostasis Assessment of Post COVID-19 Patients with Acute Myocardial Infarction. **2023**, 24, 6523 | 0 |

| 4 | Spatial analysis of human lung cancer reveals organized immune hubs enriched for stem-like CD8 T cells and associated with immunotherapy response. | 0 |

| 3 | Identification of a specific inflammatory protein biosignature in coronary and peripheral blood associated with increased risk of future cardiovascular events. | 0 |

| 2 | Circulating proteins to predict COVID-19 severity. **2023**, 13, | 0 |

| 1 | Age-related changes in plasma biomarkers and their association with mortality in COVID-19. 2300011 | 0 |